CAMBRIDGE, Mass. — MOMA Therapeutics has dosed the first patient in a Phase 1 clinical trial evaluating MOMA-341, a highly potent and selective Werner helicase inhibitor, the company announced Tuesday. The investigational therapy is being studied for its potential to treat advanced or metastatic solid tumors with high microsatellite instability (MSI-H) and/or DNA mismatch repair deficiency (dMMR).
MOMA-341 is an oral, covalent small molecule featuring a novel chemical scaffold developed through the company’s proprietary KNOMATIC™ discovery platform. It is designed to selectively inhibit the Werner helicase protein, which is essential for the survival of MSI-H/dMMR tumor cells—making it a promising new target for precision oncology.
The ongoing Phase 1 study will evaluate the safety, tolerability, and initial pharmacokinetics of MOMA-341, both as a monotherapy and in combination with chemotherapy or immunotherapy. Tumor types under investigation include colorectal, gastric, and endometrial cancers.
“We are proud to enter the clinic for the second time in less than a year, with initial readouts for both MOMA-341 and MOMA-313, our novel Polθ helicase inhibitor, expected in early-to-mid 2026,” said Dr. Asit Parikh, Chief Executive Officer of MOMA Therapeutics. “Given that MOMA-341’s novel chemical scaffold confers excellent target coverage, we are eager to evaluate its best-in-class potential for patients through this Phase 1 study.”
The company expects to report initial monotherapy data from the MOMA-341 trial in mid-2026. MOMA Therapeutics, which focuses on developing precision therapeutics targeting molecular machines, continues to expand its clinical pipeline as part of its mission to deliver transformative treatments for cancer patients.
